InsidersTradesSigma
Total declarations
Companies
▲ Purchases (2 ops.)
▼ Sales (4 ops.)
Insider track record
CFODisclosed buys
2
Disclosed sells
4
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Explore the complete record of transactions filed by WEINSTEIN ROBERT, Chief Financial Officer. Officer active across 3 companies, notably Synaptogenix, Inc.. Cumulatively, 12 reports have been logged. Split: 2 buys · 4 sells. Total volume traded: €239k. Activity tracked since 13 July 2021. The latest transaction was disclosed on 30 May 2023 (Acquisition). Regulator: SEC (Form 4). The full history is accessible without signup.
Declarations12 total
25,000 shares@ US$0.24749.7% of flowCommon StockSEC:0001062993-23-012491:0
Ideal exit: 24 Feb 2024 (T+270)
25,000 shares@ US$0.2550.3% of flowCommon StockSEC:0001062993-23-012403:0
Ideal exit: 20 Feb 2024 (T+270)
27,000 shares@ US$1.1719100.0% of flowCommon Stock, par value $0.0001 per shareSEC:0001104659-22-128771:0
45,000 shares@ US$1.0622.2% of flowCommon StockSEC:0000950138-22-000108:0
31,250 shares0Common StockSEC:0000950138-22-000034:0
31,250 shares0Common StockSEC:0000950138-22-000034
63,000 shares@ US$1.431938.9% of flowCommon StockSEC:0000950138-21-000470:0
63,000 shares@ US$1.431938.9% of flowCommon StockSEC:0000950138-21-000470
200,000 shares0Common StockSEC:0000950138-21-000394
200,000 shares0Common StockSEC:0000950138-21-000394:0
60,000 shares0Common Stock, par value $0.0001 per shareSEC:0001104659-21-092716:0
60,000 shares0Common Stock, par value $0.0001 per shareSEC:0001104659-21-092716
12 of 12 declarations
About WEINSTEIN ROBERT
Robert Weinstein is the Chief Financial Officer and Director of Synaptogenix, Inc. and XpresSpa Group, Inc. In his roles, he oversees financial management, strategic planning, and financial performance analysis for both companies. Robert plays a crucial role in optimizing financial resources and making informed decisions to support growth and profitability. His financial expertise is a valuable asset to the boards of both companies.
